PL2922576T3 - Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej - Google Patents

Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej

Info

Publication number
PL2922576T3
PL2922576T3 PL13857455T PL13857455T PL2922576T3 PL 2922576 T3 PL2922576 T3 PL 2922576T3 PL 13857455 T PL13857455 T PL 13857455T PL 13857455 T PL13857455 T PL 13857455T PL 2922576 T3 PL2922576 T3 PL 2922576T3
Authority
PL
Poland
Prior art keywords
encefalopati
hepatic
administration
evaluation
nitrogen
Prior art date
Application number
PL13857455T
Other languages
English (en)
Inventor
Bruce Scharschmidt
Masoud MOKHTARANI
Original Assignee
Horizon Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics, Llc filed Critical Horizon Therapeutics, Llc
Publication of PL2922576T3 publication Critical patent/PL2922576T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
PL13857455T 2012-11-21 2013-11-21 Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej PL2922576T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261728967P 2012-11-21 2012-11-21
US201361759292P 2013-01-31 2013-01-31
PCT/US2013/071333 WO2014081977A1 (en) 2012-11-21 2013-11-21 Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
EP13857455.3A EP2922576B1 (en) 2012-11-21 2013-11-21 Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy

Publications (1)

Publication Number Publication Date
PL2922576T3 true PL2922576T3 (pl) 2018-08-31

Family

ID=50728524

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13857455T PL2922576T3 (pl) 2012-11-21 2013-11-21 Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej

Country Status (21)

Country Link
US (3) US9289406B2 (pl)
EP (2) EP2922576B1 (pl)
JP (1) JP2016506378A (pl)
KR (1) KR20150086510A (pl)
CN (1) CN104797272A (pl)
AU (1) AU2013347905B2 (pl)
BR (1) BR112015011778A2 (pl)
CA (1) CA2891657A1 (pl)
CY (1) CY1120163T1 (pl)
DK (1) DK2922576T3 (pl)
ES (1) ES2654774T3 (pl)
HK (1) HK1210699A1 (pl)
HR (1) HRP20180041T1 (pl)
HU (1) HUE036133T2 (pl)
LT (1) LT2922576T (pl)
PL (1) PL2922576T3 (pl)
PT (1) PT2922576T (pl)
RS (1) RS56757B1 (pl)
SI (1) SI2922576T1 (pl)
SM (1) SMT201800022T1 (pl)
WO (1) WO2014081977A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2652187T3 (es) 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
EP2440200B8 (en) 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate
SI2760479T1 (sl) 2011-09-30 2017-07-31 Horizon Therapeutics, Llc Zdravilo, ki odstranjuje dušik, za uporabo v postopku zdravljenja motnje retencije dušika
RS55870B1 (sr) 2012-04-20 2017-08-31 Horizon Therapeutics Llc Hpn-100 za upotrebu u lečenju poremećaja nakupljanja azota
SMT201800022T1 (it) * 2012-11-21 2018-03-08 Horizon Therapeutics Llc Metodi per somministrare e valutare farmaci di rimozione dell'azoto per il trattamento di encefalopatia epatica
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
CN110740988A (zh) 2017-05-11 2020-01-31 欧塞拉治疗有限公司 制备l-鸟氨酸苯乙酸盐的方法
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
MX2023002868A (es) 2020-09-14 2023-03-24 Wellstat Therapeutics Corp 2',3'-diacetiluridina sustituida por acetoacetilo en la posicion 5'.
MX2023006343A (es) * 2020-12-01 2023-06-12 Wellstat Therapeutics Corp 5'-o-fenilacetiluridina y uso terapeutico.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
CA2212047C (en) 1995-02-07 2010-11-16 Saul W. Brusilow Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
US6219567B1 (en) 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
CN1778963A (zh) * 2004-11-23 2006-05-31 苏州艾杰生物科技有限公司 血氨含量测定方法及血氨诊断试剂盒
ES2448549T3 (es) 2004-11-26 2014-03-14 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
WO2007059031A2 (en) 2005-11-10 2007-05-24 Massachusetts Institute Of Technology Methods and compositions for raising levels and release of gamma aminobutyric acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
GB2465250B (en) 2008-08-29 2011-01-26 Ucyclyd Pharma Inc Dosing and monitoring patients on nitrogen-scavenging drugs
PL3133396T3 (pl) 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
ES2593378T3 (es) * 2008-08-29 2016-12-09 Horizon Therapeutics, Llc Métodos de tratamiento usando fármacos de secuestro de ammonia
EP2456304B1 (en) 2009-07-24 2015-08-19 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
US20130224277A1 (en) 2010-08-31 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation
SI2760479T1 (sl) * 2011-09-30 2017-07-31 Horizon Therapeutics, Llc Zdravilo, ki odstranjuje dušik, za uporabo v postopku zdravljenja motnje retencije dušika
RS55870B1 (sr) 2012-04-20 2017-08-31 Horizon Therapeutics Llc Hpn-100 za upotrebu u lečenju poremećaja nakupljanja azota
SMT201800022T1 (it) * 2012-11-21 2018-03-08 Horizon Therapeutics Llc Metodi per somministrare e valutare farmaci di rimozione dell'azoto per il trattamento di encefalopatia epatica
WO2015048818A1 (en) 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Diagnosing, grading, monitoring, and treating hepatic encephalopathy
SI2986325T1 (sl) 2013-10-14 2020-02-28 Immedica Pharma Ab Postopki zdravljenja motenj ciklusa sečnine

Also Published As

Publication number Publication date
HUE036133T2 (hu) 2018-06-28
US9289406B2 (en) 2016-03-22
US20160223520A1 (en) 2016-08-04
HK1210699A1 (en) 2016-05-06
WO2014081977A1 (en) 2014-05-30
CA2891657A1 (en) 2014-05-30
US20180017546A1 (en) 2018-01-18
BR112015011778A2 (pt) 2017-07-11
SMT201800022T1 (it) 2018-03-08
KR20150086510A (ko) 2015-07-28
HK1213778A1 (en) 2016-07-15
US20140142186A1 (en) 2014-05-22
CN104797272A (zh) 2015-07-22
CY1120163T1 (el) 2018-12-12
EP2922576A4 (en) 2016-05-04
AU2013347905B2 (en) 2018-10-04
JP2016506378A (ja) 2016-03-03
AU2013347905A1 (en) 2015-04-30
SI2922576T1 (en) 2018-04-30
ES2654774T3 (es) 2018-02-15
EP2922576B1 (en) 2017-11-08
DK2922576T3 (en) 2018-01-15
RS56757B1 (sr) 2018-04-30
PT2922576T (pt) 2018-01-24
LT2922576T (lt) 2018-02-12
HRP20180041T1 (hr) 2018-06-01
EP2922576A1 (en) 2015-09-30
EP3335735A1 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
CY1125560T1 (el) Πολυκυκλικες ενωσεις καρβαμοϋλπυριδονης και φαρμακευτικη χρηση αυτων
DK3639872T3 (da) Lægemiddeladministrationsanordning
HRP20260139T1 (hr) Farmaceutski pripravak, postupci za liječenje i njegove uporabe
EP3065808C0 (en) DEVICES AND METHODS FOR CONTINUOUS ORAL DRUG DELIVERY
IL230786A0 (en) Heterocyclic derivative and pharmaceutical drug
EP2922877A4 (en) IMPROVED PEPTIDATE MEDICINES
HRP20181855T1 (hr) Lipidi za formulacije namijenjene unosu terapijskog sredstva
IL244089A0 (en) Diagnostic methods and compositions for treatment of glioblastoma
EP2804599A4 (en) PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
HRP20180041T1 (hr) Postupci davanja i procjene lijekova za uklanjanje dušika za liječenje jetrene encefalopatije
PL2842945T3 (pl) Pochodna sulfonamidowa i jej zastosowanie medyczne
IL229963A0 (en) Substituted quinolines and their use as medicaments
HRP20182156T1 (hr) Kationi trialkil lipida i postupci za njihovu uporabu
IL235768A0 (en) Pharmaceutical compositions and treatment of mastitis
PT3064491T (pt) Derivado de sulfonamida e sua utilização medicinal
PT2968368T (pt) Administração craniana de substâncias farmacêuticas
IL262252B (en) Therapeutic compositions and methods involving mrna transfection
IL234606B (en) Novel methods and composition for treatment of disease
DK3079655T3 (da) Inhalerbare lægemidler
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
DK2964193T3 (da) Lægemidler til oral indgivelse
IL233875A (en) Composition and use thereof in the treatment of anal rhagades
IL242355B (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
DK3473255T3 (da) Farmaceutisk formulering omfattende ciclesonid
DK2897588T3 (da) Inhalerbart lægemiddel